Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.62 |
| ▸ | NPC1 | O15118 | 2/20 | 0.62 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.53 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29132046 | 0.92 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL22835746 | 0.91 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL26351486 | 0.91 | SMN1; SMN2 (0.61) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL458805 | 0.90 | SMN1; SMN2 (0.72) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL29927302 | 0.88 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL29927996 | 0.88 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL23124998 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL23125002 | 0.87 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL26271938 | 0.87 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B | |
| SCHEMBL29132155 | 0.87 | SMN1; SMN2 (0.58) | SMN1; SMN2NPC1RAB9ACYP2C19GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | ARVINAS OPERATIONS, INC. (US) | 2026-03-31 | — | — | US | disclosed |
| US-20250228952-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | ARVINAS OPERATIONS, INC. | 2025-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228952-A1 | BENZIMIDAZOLE AND BENZIMIDAZOLONE BASED PROTAC COMPOUNDS FOR THE TARGETED DEGRADATION OF LEUCINE RICH REPEAT KINASE 2 (LRRK2) | LRRK2, PINK1, PSMC1 | SMN1; SMN2 1261/4885NPC1 3081/4885RAB9A 1427/4885 |
| US-12589156-B2 | Benzimidazole and benzimidazolone based protac compounds for the targeted degradation of leucine rich repeat kinase 2 (LRRK2) | LRRK2, SNCA, PARK7 | SMN1; SMN2 89/4885NPC1 3228/4885RAB9A 1303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.